Lonza, the Swiss company tasked with mass production of Moderna’s COVID-19 vaccine, expects the first batches for widespread public use to go out in December. Interim CEO and Chairman Albert Baehny tells CNNMoney that the vaccine will initially be made in the U.S., with a production line in Switzerland also planned. Lonza’s stock surged Monday after Moderna reported positive early results from a Phase 1 clinical trial, which focuses on whether a vaccine is safe and elicits an immune response. The Food and Drug Administration has cleared the U.S. biotech company to begin Phase 2 trials, which typically involve several hundred of people, and Moderna plans to start large-scale clinical trials in July.
